教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling. |
掲載誌名 | 正式名:British journal of cancer 略 称:Br J Cancer ISSNコード:1532-1827(Electronic)0007-0920(Linking) |
巻・号・頁 | 111(4),pp.763-71 |
著者・共著者 | Fukui Hirokazu, Zhang X, Sun C, Hara Ken, Kikuchi Syojiro, Yamasaki Takatoshi, Kondo Takashi, Tomita Toshihiko, Oshima Tadayuki, Watari Jiro, Imura J, Fujimori T, Sasako Mitsuru, Miwa Hiroto |
発行年月 | 2014/06 |
概要 | UNLABELLED:Background:Interleukin-22 (IL-22) has been recently highlighted owing to its biological significance in the modulation of tissue responses during inflammation. However, the role of IL-22 in carcinogenesis has remained unclear. Here, we investigated the pathophysiological significance of IL-22 expression in gastric cancer tissues and examined the mechanism by which IL-22 promotes gastric cancer cell invasion.Methods:Human gastric cancer specimens were analysed by immunohistochemistry for expression of IL-22 and IL-22 receptor 1 (IL-22R1). The effects of IL-22-induced STAT3 and ERK signalling on invasive ability of gastric cancer cells were examined using a small-interfering RNA system and specific inhibitUNLABELLED:ors. AGS cells were co-cultured with cancer-associated fibroblasts (CAFs) from human gastric cancer tissues and assessed by invasion assay.Results:Interleukin-22 and its receptor were expressed in α-smooth muscle actin-positive stromal cells and tumour cells at the invasive front of gastric cancer tissues, respectively. The expression of IL-22 and IL-22R1 was significantly related to lymphatic invasion. Interleukin-22 treatment promoted the invasive ability of gastric cancer cells through STAT3 and ERK activation. The invasive ability of gastric cancer cells was significantly enhanced by co-culture with IL-22-expressing CAFs.Conclusions:Interleukin-22 produced by CAFs promotes gastric cancer cell invasion via STAT3 and ERK signalling.British Journal of Cancer advance online publication 17 June 2014; doi:10.1038/bjc.2014.336 www.bjcancer.com. |
DOI | 10.1038/bjc.2014.336 |
PMID | 24937671 |